Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Macitentan reduces progression of TGF-β1-induced pulmonary fibrosis and pulmonary hypertension.

Bellaye PS, Yanagihara T, Granton E, Sato S, Shimbori C, Upagupta C, Imani J, Hambly N, Ask K, Gauldie J, Iglarz M, Kolb M.

Eur Respir J. 2018 Jul 5. pii: 1701857. doi: 10.1183/13993003.01857-2017. [Epub ahead of print] No abstract available.

PMID:
29976656
2.

Selective Prostacyclin Receptor Agonist Selexipag, in Contrast to Prostacyclin Analogs, Does Not Evoke Paradoxical Vasoconstriction of the Rat Femoral Artery.

Morrison K, Haag F, Ernst R, Iglarz M, Clozel M.

J Pharmacol Exp Ther. 2018 Jun;365(3):727-733. doi: 10.1124/jpet.117.246058. Epub 2018 Mar 27.

PMID:
29588339
3.

Granulomatous lung inflammation is nanoparticle type-dependent.

Pacheco Y, Ponchon M, Lebecque S, Calender A, Bernaudin JF, Valeyre D, Iglarz M, Strasser DS, Studer R, Freti D, Renno T, Bentaher A.

Exp Lung Res. 2018 Feb;44(1):25-39. doi: 10.1080/01902148.2017.1412541. Epub 2018 Jan 11.

PMID:
29324063
4.

Selective improvement of pulmonary arterial hypertension with a dual ETA/ETB receptors antagonist in the apolipoprotein E-/- model of PAH and atherosclerosis.

Renshall L, Arnold N, West L, Braithwaite A, Pickworth J, Walker R, Alfaidi M, Chamberlain J, Casbolt H, Thompson AAR, Holt C, Iglarz M, Francis S, Lawrie A.

Pulm Circ. 2018 Jan-Mar;8(1):2045893217752328. doi: 10.1177/2045893217752328. Epub 2017 Dec 20.

5.

Dual ETA/ETB blockade with macitentan improves both vascular remodeling and angiogenesis in pulmonary arterial hypertension.

Nadeau V, Potus F, Boucherat O, Paradis R, Tremblay E, Iglarz M, Paulin R, Bonnet S, Provencher S.

Pulm Circ. 2018 Jan-Mar;8(1):2045893217741429. doi: 10.1177/2045893217741429. Epub 2017 Oct 24.

6.

Selexipag Active Metabolite ACT-333679 Displays Strong Anticontractile and Antiremodeling Effects but Low β-Arrestin Recruitment and Desensitization Potential.

Gatfield J, Menyhart K, Wanner D, Gnerre C, Monnier L, Morrison K, Hess P, Iglarz M, Clozel M, Nayler O.

J Pharmacol Exp Ther. 2017 Jul;362(1):186-199. doi: 10.1124/jpet.116.239665. Epub 2017 May 5.

7.

Endothelin ETA Receptor Blockade, by Activating ETB Receptors, Increases Vascular Permeability and Induces Exaggerated Fluid Retention.

Vercauteren M, Trensz F, Pasquali A, Cattaneo C, Strasser DS, Hess P, Iglarz M, Clozel M.

J Pharmacol Exp Ther. 2017 May;361(2):322-333. doi: 10.1124/jpet.116.234930. Epub 2017 Feb 21.

8.

Dual Endothelin-A/Endothelin-B Receptor Blockade and Cardiac Remodeling in Heart Failure With Preserved Ejection Fraction.

Valero-Munoz M, Li S, Wilson RM, Boldbaatar B, Iglarz M, Sam F.

Circ Heart Fail. 2016 Nov;9(11). pii: e003381.

9.

Endothelin receptor antagonist macitentan or deletion of mouse mast cell protease 4 delays lesion development in atherosclerotic mice.

Houde M, Desbiens L, Schwertani A, Pejler G, Iglarz M, D'Orléans-Juste P.

Life Sci. 2016 Aug 15;159:71-75. doi: 10.1016/j.lfs.2016.03.018. Epub 2016 Mar 12.

PMID:
26976326
10.

The Endothelial-mesenchymal Transition in Systemic Sclerosis Is Induced by Endothelin-1 and Transforming Growth Factor-β and May Be Blocked by Macitentan, a Dual Endothelin-1 Receptor Antagonist.

Cipriani P, Di Benedetto P, Ruscitti P, Capece D, Zazzeroni F, Liakouli V, Pantano I, Berardicurti O, Carubbi F, Pecetti G, Turricchia S, Alesse E, Iglarz M, Giacomelli R.

J Rheumatol. 2015 Oct;42(10):1808-16. doi: 10.3899/jrheum.150088. Epub 2015 Aug 15.

PMID:
26276964
11.

Discovery of novel bridged tetrahydronaphthalene derivatives as potent T/L-type calcium channel blockers.

Renneberg D, Hubler F, Rey M, Hess P, Delahaye S, Gatfield J, Iglarz M, Hilpert K.

Bioorg Med Chem Lett. 2015 Sep 15;25(18):3941-6. doi: 10.1016/j.bmcl.2015.07.038. Epub 2015 Jul 21.

PMID:
26231163
12.

Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension.

Iglarz M, Landskroner K, Bauer Y, Vercauteren M, Rey M, Renault B, Studer R, Vezzali E, Freti D, Hadana H, Schläpfer M, Cattaneo C, Bortolamiol C, Weber E, Whitby BR, Delahaye S, Wanner D, Steiner P, Nayler O, Hess P, Clozel M.

J Cardiovasc Pharmacol. 2015 Nov;66(5):457-67. doi: 10.1097/FJC.0000000000000296.

13.

Chymase: a multifunctional player in pulmonary hypertension associated with lung fibrosis.

Kosanovic D, Luitel H, Dahal BK, Cornitescu T, Janssen W, Danser AH, Garrelds IM, De Mey JG, Fazzi G, Schiffers P, Iglarz M, Fischli W, Ghofrani HA, Weissmann N, Grimminger F, Seeger W, Reiss I, Schermuly RT.

Eur Respir J. 2015 Oct;46(4):1084-94. doi: 10.1183/09031936.00018215. Epub 2015 Jun 25.

14.

Treatment of obesity and pulmonary arterial hypertension with inhibitors of the prostaglandin transporter: evaluation of patent WO2014/204895A1.

Dingemanse J, Bolli M, Iglarz M.

Expert Opin Ther Pat. 2015;25(9):1069-77. doi: 10.1517/13543776.2015.1056152. Epub 2015 Jun 24.

PMID:
26099857
15.

Vascular Effects of Endothelin Receptor Antagonists Depends on Their Selectivity for ETA Versus ETB Receptors and on the Functionality of Endothelial ETB Receptors.

Iglarz M, Steiner P, Wanner D, Rey M, Hess P, Clozel M.

J Cardiovasc Pharmacol. 2015 Oct;66(4):332-7. doi: 10.1097/FJC.0000000000000283.

16.

Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension.

Iglarz M, Bossu A, Wanner D, Bortolamiol C, Rey M, Hess P, Clozel M.

Life Sci. 2014 Nov 24;118(2):333-9. doi: 10.1016/j.lfs.2014.02.018. Epub 2014 Feb 26.

17.

Macitentan slows down the dermal fibrotic process in systemic sclerosis: in vitro findings.

Corallo C, Pecetti G, Iglarz M, Volpi N, Franci D, Montella A, D' Onofrio F, Nuti R, Giordano N.

J Biol Regul Homeost Agents. 2013 Apr-Jun;27(2):455-62.

PMID:
23830395
18.

The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist.

Bolli MH, Boss C, Binkert C, Buchmann S, Bur D, Hess P, Iglarz M, Meyer S, Rein J, Rey M, Treiber A, Clozel M, Fischli W, Weller T.

J Med Chem. 2012 Sep 13;55(17):7849-61. doi: 10.1021/jm3009103. Epub 2012 Aug 16.

PMID:
22862294
19.

Renal, retinal and cardiac changes in type 2 diabetes are attenuated by macitentan, a dual endothelin receptor antagonist.

Sen S, Chen S, Feng B, Iglarz M, Chakrabarti S.

Life Sci. 2012 Oct 15;91(13-14):658-68. doi: 10.1016/j.lfs.2012.03.032. Epub 2012 Apr 13.

20.

At the heart of tissue: endothelin system and end-organ damage.

Iglarz M, Clozel M.

Clin Sci (Lond). 2010 Aug 17;119(11):453-63. doi: 10.1042/CS20100222. Review.

PMID:
20712600
21.

Identification of a novel role for endothelins within the oviduct.

Jeoung M, Lee S, Hawng HK, Cheon YP, Jeong YK, Gye MC, Iglarz M, Ko C, Bridges PJ.

Endocrinology. 2010 Jun;151(6):2858-67. doi: 10.1210/en.2009-1155. Epub 2010 Mar 31.

22.

Countervailing vascular effects of rosiglitazone in high cardiovascular risk mice: role of oxidative stress and PRMT-1.

Savoia C, Ebrahimian T, Lemarié CA, Paradis P, Iglarz M, Amiri F, Javeshgani D, Schiffrin EL.

Clin Sci (Lond). 2010 Feb 9;118(9):583-92. doi: 10.1042/CS20090289.

PMID:
19951259
23.

Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist.

Iglarz M, Binkert C, Morrison K, Fischli W, Gatfield J, Treiber A, Weller T, Bolli MH, Boss C, Buchmann S, Capeleto B, Hess P, Qiu C, Clozel M.

J Pharmacol Exp Ther. 2008 Dec;327(3):736-45. doi: 10.1124/jpet.108.142976. Epub 2008 Sep 9.

24.

Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP.

Pu Q, Brassard P, Javeshghani DM, Iglarz M, Webb RL, Amiri F, Schiffrin EL.

J Hypertens. 2008 Feb;26(2):322-33. doi: 10.1097/HJH.0b013e3282f16aaf.

PMID:
18192847
25.

Mechanisms of ET-1-induced endothelial dysfunction.

Iglarz M, Clozel M.

J Cardiovasc Pharmacol. 2007 Dec;50(6):621-8. Review.

PMID:
18091577
26.

Endothelin-2 induces oviductal contraction via endothelin receptor subtype A in rats.

Al-Alem L, Bridges PJ, Su W, Gong MC, Iglarz M, Ko C.

J Endocrinol. 2007 Jun;193(3):383-91.

27.

Synergistic vascular protective effects of combined low doses of PPARalpha and PPARgamma activators in angiotensin II-induced hypertension in rats.

De Ciuceis C, Amiri F, Iglarz M, Cohn JS, Touyz RM, Schiffrin EL.

Br J Pharmacol. 2007 May;151(1):45-53. Epub 2007 Mar 12.

28.

Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats.

Clozel M, Hess P, Rey M, Iglarz M, Binkert C, Qiu C.

Exp Biol Med (Maywood). 2006 Jun;231(6):967-73.

PMID:
16741032
29.

Endothelin-2 in ovarian follicle rupture.

Ko C, Gieske MC, Al-Alem L, Hahn Y, Su W, Gong MC, Iglarz M, Koo Y.

Endocrinology. 2006 Apr;147(4):1770-9. Epub 2006 Jan 12.

PMID:
16410304
30.

Position of Src tyrosine kinases in the interaction between angiotensin II and endothelin in in vivo vascular protein synthesis.

Beaucage P, Iglarz M, Servant M, Touyz RM, Moreau P.

J Hypertens. 2005 Feb;23(2):329-35.

PMID:
15662221
31.

Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction.

Amiri F, Virdis A, Neves MF, Iglarz M, Seidah NG, Touyz RM, Reudelhuber TL, Schiffrin EL.

Circulation. 2004 Oct 12;110(15):2233-40. Epub 2004 Oct 4.

PMID:
15466627
32.

Involvement of oxidative stress in the profibrotic action of aldosterone. Interaction wtih the renin-angiotension system.

Iglarz M, Touyz RM, Viel EC, Amiri F, Schiffrin EL.

Am J Hypertens. 2004 Jul;17(7):597-603.

PMID:
15243979
33.

Chronic decrease in flow contributes to heart failure-induced endothelial dysfunction in rats.

Devaux C, Iglarz M, Richard V, Mulder P, Henrion D, Renet S, Henry JP, Thuillez C.

Clin Exp Pharmacol Physiol. 2004 May-Jun;31(5-6):302-5.

PMID:
15191402
34.

Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats.

Endemann DH, Touyz RM, Iglarz M, Savoia C, Schiffrin EL.

Hypertension. 2004 Jun;43(6):1252-7. Epub 2004 Apr 26.

PMID:
15117913
35.

Peroxisome proliferator-activated receptors: vascular and cardiac effects in hypertension.

Schiffrin EL, Amiri F, Benkirane K, Iglarz M, Diep QN.

Hypertension. 2003 Oct;42(4):664-8. Epub 2003 Jul 21.

PMID:
12874098
36.

Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension.

Iglarz M, Touyz RM, Viel EC, Paradis P, Amiri F, Diep QN, Schiffrin EL.

Hypertension. 2003 Oct;42(4):737-43. Epub 2003 Jul 14.

PMID:
12860836
37.

Effect of hyperhomocystinemia and hypertension on endothelial function in methylenetetrahydrofolate reductase-deficient mice.

Virdis A, Iglarz M, Neves MF, Amiri F, Touyz RM, Rozen R, Schiffrin EL.

Arterioscler Thromb Vasc Biol. 2003 Aug 1;23(8):1352-7. Epub 2003 Jun 26.

PMID:
12829522
38.

Role of endothelin-1 in hypertension.

Iglarz M, Schiffrin EL.

Curr Hypertens Rep. 2003 Apr;5(2):144-8. Review.

PMID:
12642014
39.

Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension.

Iglarz M, Touyz RM, Amiri F, Lavoie MF, Diep QN, Schiffrin EL.

Arterioscler Thromb Vasc Biol. 2003 Jan 1;23(1):45-51.

PMID:
12524223
40.

Antiangiogenic effect of angiotensin II type 2 receptor in ischemia-induced angiogenesis in mice hindlimb.

Silvestre JS, Tamarat R, Senbonmatsu T, Icchiki T, Ebrahimian T, Iglarz M, Besnard S, Duriez M, Inagami T, Lévy BI.

Circ Res. 2002 May 31;90(10):1072-9.

PMID:
12039796
41.

Preproendothelin-1 gene polymorphism is related to a change in vascular reactivity in the human mammary artery in vitro.

Iglarz M, Benessiano J, Philip I, Vuillaumier-Barrot S, Lasocki S, Hvass U, Durand G, Desmonts JM, Lévy BI, Henrion D.

Hypertension. 2002 Feb;39(2):209-13.

PMID:
11847185
42.

Involvement of renin-angiotensin system in pressure-flow relationship: role of angiotensin-converting enzyme gene polymorphism.

Lasocki S, Iglarz M, Seince PF, Vuillaumier-Barrot S, Vicaut E, Henrion D, Levy B, Desmonts JM, Philip I, Bénessiano J.

Anesthesiology. 2002 Feb;96(2):271-5.

PMID:
11818755
43.

Genetic determinants of vascular reactivity.

Henrion D, Benessiano J, Iglarz M, Philip I, Levy BI.

Curr Hypertens Rep. 2002 Feb;4(1):41-8. Review.

PMID:
11790291
44.

Chronic blockade of endothelin receptors improves ischemia-induced angiogenesis in rat hindlimbs through activation of vascular endothelial growth factor-no pathway.

Iglarz M, Silvestre JS, Duriez M, Henrion D, Lévy BI.

Arterioscler Thromb Vasc Biol. 2001 Oct;21(10):1598-603.

PMID:
11597932
45.

The deletion genotype of the angiotensin I-converting enzyme is associated with an increased vascular reactivity in vivo and in vitro.

Henrion D, Benessiano J, Philip I, Vuillaumier-Barrot S, Iglarz M, Plantefève G, Chatel D, Hvass U, Durand G, Desmonts JM, Amouyel P, Lévy BI.

J Am Coll Cardiol. 1999 Sep;34(3):830-6.

46.
47.
48.

Chronic blockade of endothelin ETA receptors improves flow dependent dilation in resistance arteries of hypertensive rats.

Iglarz M, Matrougui K, Lévy BI, Henrion D.

Cardiovasc Res. 1998 Sep;39(3):657-64.

PMID:
9861309
49.

Chronic endothelin-1-induced changes in vascular reactivity in rat resistance arteries and aorta.

Iglarz M, Lévy BI, Henrion D.

Eur J Pharmacol. 1998 Oct 16;359(1):69-75.

PMID:
9831295
50.

Determination of 2-n-propylquinoline in mouse plasma and liver by high-performance liquid chromatography.

Iglarz M, Baune B, Gantier JC, Hocquemiller R, Farinotti R.

J Chromatogr B Biomed Sci Appl. 1998 Sep 4;714(2):335-40.

PMID:
9766874

Supplemental Content

Loading ...
Support Center